Nanopath Inc. is at the forefront of developing innovative diagnostic technologies aimed at enhancing women's health through a pioneering molecular diagnostic platform. This platform is designed for point-of-care disease diagnosis, allowing for rapid and accurate detection of various pathogens, including viral, bacterial, and fungal agents. Notably, the technology does not require nucleic acid amplification, which significantly reduces the time needed to obtain results. Additionally, it can simultaneously detect multiple targets from a single patient sample, making it a versatile tool in clinical settings. The company's focus on infectious diseases that predominantly affect women, such as urinary tract infections and sexually transmitted infections, underscores its commitment to addressing critical health issues.

The interdisciplinary team at Nanopath leverages advancements in nanotechnology, biosensing, optics, and molecular biology to push the boundaries of diagnostic capabilities. Their cartridge and reader system is designed to bring comprehensive testing directly to healthcare providers, promoting proactive patient care and informed clinical decision-making. The innovative nature of Nanopath's technology has been recognized with awards, including the 2022 Disruptive Technology Award from the Association for Diagnostics & Laboratory Medicine, highlighting its potential to transform patient care. With backing from the NIH and NSF, Nanopath is poised to make significant contributions to the field of diagnostics, with applications that extend beyond women's health.

United States

Nanopath Inc. is a molecular diagnostics company enabling high-quality molecular testing in minutes. The company is commercializing a first-in-class molecular diagnostic platform to enable scalable, point-of-care disease diagnosis.

Nanopath Inc.

Company Details